ROCK1 and metabolic dysfunction-associated steatohepatitis: Y-27632 (Fig. 1) is a promising selective ROCK1 inhibitor with an IC50 value of 0.046 μM that restrain the progression of liver steatosis and fibrosis in NASH rat model [29].